ES2063183T3 - Oligonucleotidos antisentido para la inhibicion de la secuencia diana del transactivador (tar) y de la sintesis de la proteina transactivadora (tat) de hiv-i y su uso. - Google Patents

Oligonucleotidos antisentido para la inhibicion de la secuencia diana del transactivador (tar) y de la sintesis de la proteina transactivadora (tat) de hiv-i y su uso.

Info

Publication number
ES2063183T3
ES2063183T3 ES90103641T ES90103641T ES2063183T3 ES 2063183 T3 ES2063183 T3 ES 2063183T3 ES 90103641 T ES90103641 T ES 90103641T ES 90103641 T ES90103641 T ES 90103641T ES 2063183 T3 ES2063183 T3 ES 2063183T3
Authority
ES
Spain
Prior art keywords
transactivator
hiv
tat
tar
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90103641T
Other languages
English (en)
Inventor
Udo Dr Stropp
Jorg Dr Baumgarten
Antonius Dr Lobberding
Wolfgang Dr Springer
Norbert Dr Piel
Axel Dr Kretschmer
Heinz Dr Z Zt Mobay Corp Kolbl
Werner Prof Dr Frommer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Application granted granted Critical
Publication of ES2063183T3 publication Critical patent/ES2063183T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EL PRESENTE INVENTO SE REFIERE A UN OLIGONUCLEOTIDO ANTITIPO MODIFICADO QUIMICAMENTE, QUE SE UTILIZA PARA INHIBIR LA SECUENCIA TRANSACTIVADORA (TAR) Y LA SINTESIS DE PROTEINAS TRANSACTIVADORAS (TAT) DE (HIV-I); SE EMPLEA COMO MEDICAMENTO EN LA TERAPIA DE INFECCIONES (HIV-I); PRESENTA UNA ACTIVIDAD ANTIVIRAL Y ES APROPIADA COMO EMISORES DE GENES PARA LA DETECCION DE HIV.
ES90103641T 1989-03-09 1990-02-25 Oligonucleotidos antisentido para la inhibicion de la secuencia diana del transactivador (tar) y de la sintesis de la proteina transactivadora (tat) de hiv-i y su uso. Expired - Lifetime ES2063183T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3907562A DE3907562A1 (de) 1989-03-09 1989-03-09 Antisense-oligonukleotide zur inhibierung der transaktivatorzielsequenz (tar) und der synthese des transaktivatorproteins (tat) aus hiv-1 und deren verwendung

Publications (1)

Publication Number Publication Date
ES2063183T3 true ES2063183T3 (es) 1995-01-01

Family

ID=6375881

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90103641T Expired - Lifetime ES2063183T3 (es) 1989-03-09 1990-02-25 Oligonucleotidos antisentido para la inhibicion de la secuencia diana del transactivador (tar) y de la sintesis de la proteina transactivadora (tat) de hiv-i y su uso.

Country Status (5)

Country Link
EP (1) EP0386563B1 (es)
JP (1) JPH02276577A (es)
AT (1) ATE105020T1 (es)
DE (2) DE3907562A1 (es)
ES (1) ES2063183T3 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866698A (en) * 1990-05-04 1999-02-02 Isis Pharmaceuticals, Inc. Modulation of gene expression through interference with RNA secondary structure
US6034233A (en) * 1990-05-04 2000-03-07 Isis Pharmaceuticals Inc. 2'-O-alkylated oligoribonucleotides and phosphorothioate analogs complementary to portions of the HIV genome
WO1991017246A1 (en) * 1990-05-04 1991-11-14 Isis Pharmaceuticals, Inc. Modulation of gene expression through interference with rna secondary structure
US5166195A (en) * 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
GB9016973D0 (en) * 1990-08-02 1990-09-19 Medical Res Council Viral growth inhibition
GB9020541D0 (en) * 1990-09-20 1990-10-31 Medical Res Council Viral growth inhibition
ES2335720T3 (es) 1991-01-21 2010-03-31 Elan Pharmaceuticals, Inc. Ensayo y modelo para la enfermedad de alzheimer.
FR2677039B1 (fr) * 1991-05-31 1994-09-09 Cis Bio Int Oligonucleotides, utilisables comme reactifs pour la detection in vitro des infections a retrovirus de type hiv et procede de detection de retrovirus de type hiv.
IT1250722B (it) * 1991-07-30 1995-04-21 Univ Degli Studi Milano Oligonucleotidi antisenso
US5646267A (en) * 1991-08-05 1997-07-08 Polish Academy Of Sciences Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
US5359052A (en) * 1991-08-05 1994-10-25 Polish Academy Of Sciences Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
EP0652972B1 (en) * 1992-07-20 2004-11-17 Isis Pharmaceuticals, Inc. Pseudo-half-knot rna formation by hybridization of antisense oligonucleotides to target rna's secondary structure
CN1124980A (zh) * 1993-03-31 1996-06-19 海布里顿公司 具有改良抗流感活性的经修饰寡核苷酸
CA2165821C (en) * 1993-06-23 2002-01-08 Albert D. Friesen Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
ATE239787T1 (de) * 1993-07-19 2003-05-15 Gen Probe Inc Oligonukleotide mit wirkung gegen den menschlichen immunodefiziens-virus
AU2419595A (en) * 1994-05-10 1995-11-29 Hisamitsu Pharmaceutical Co., Inc. Recombinant human immunodeficiency virus vector and process for producing the same
DE19514089C2 (de) * 1995-04-13 1997-07-10 Deutsches Krebsforsch Nachweisverfahren für HIV-TAT
US6426412B1 (en) * 1995-12-20 2002-07-30 Subsidiary No. 3, Inc. Nucleic acids encoding human immunodeficiency virus type 1 genetic suppressor elements
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
US5955644A (en) * 1996-08-08 1999-09-21 M.D. Anderson Cancer Center Ku deficient cells and non-human transgenic animals
US6057489A (en) * 1996-09-12 2000-05-02 M.D. Anderson Cancer Center MmRad51-deficient cells and transgenic mice
GB0012497D0 (en) * 2000-05-23 2000-07-12 Syngenix Ltd Antiviral therapy
AU2001263708A1 (en) * 2000-07-03 2002-01-14 Werner Alex Hafner Method for formulating molecular probes
WO2002096910A1 (en) 2001-05-31 2002-12-05 Medarex, Inc. Cytotoxins, prodrugs, linkers and stabilizers useful therefor
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
CA2623652C (en) 2005-09-26 2013-11-26 Medarex, Inc. Antibody-drug conjugates and methods of use
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
SI2056845T1 (en) 2006-08-08 2018-02-28 Rheinische Friedrich-Wilhelms-Universitaet Bonn STRUCTURE AND USE 5 'PHOSPHATE OF OLIGONUCLEOTES
EP3255144A1 (en) 2007-08-10 2017-12-13 E. R. Squibb & Sons, L.L.C. Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin
EP2297323A1 (en) 2008-05-21 2011-03-23 Hartmann, Gunther 5' triphosphate oligonucleotide with blunt end and uses thereof
IT1397569B1 (it) 2009-12-10 2013-01-16 Icgeb Peptidi e loro derivati che inibiscono il rilascio extracellulare della proteina tat di hiv-1 e la replicazione di hiv-1.
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products

Also Published As

Publication number Publication date
EP0386563A1 (de) 1990-09-12
JPH02276577A (ja) 1990-11-13
DE59005494D1 (de) 1994-06-01
DE3907562A1 (de) 1990-09-13
ATE105020T1 (de) 1994-05-15
EP0386563B1 (de) 1994-04-27

Similar Documents

Publication Publication Date Title
ES2063183T3 (es) Oligonucleotidos antisentido para la inhibicion de la secuencia diana del transactivador (tar) y de la sintesis de la proteina transactivadora (tat) de hiv-i y su uso.
Franza Jr et al. Characterization of cellular proteins recognizing the HIV enhancer using a microscale DNA-affinity precipitation assay
KR930700525A (ko) 인체 면역결핍 바이러스의 안티센스 억제제
DE69201564D1 (de) Verwendung von metalloxidmanopigmenten zum schutz von haarkeratin vor äusseren einflüssen, insbesondere sonnenlicht, verfahren zum schutz des haares und gelzusammensetzung unter verwendung dieser nanopigmente.
DE3852714D1 (de) Oligodesoxynukleotide als Inhibitoren der Replikation von Retroviren und der Expression von Onkogenen.
TR199900848T2 (xx) Oksadiazoller, elde edilmeleri ve ila� olarak kullan�mlar�.
MX9207334A (es) Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene
ES2058566T3 (es) Sondas de hibridacion para detectar las cepas de neisseria.
ATE252552T1 (de) Hemmung von hiv-1 replikation mittels oligocarbamat-derivaten
DE3881204D1 (de) Molekuele mit mindestens einer peptidsequenz einer oder mehrerer epitopen eines p.falciparum-produzierten proteins in hepatozyten und zusammensetzungen davon.
DK0497816T3 (da) Behandling af HIV-infektioner og forbindelser anvendelige derved
ATE70280T1 (de) Charakteristische polypeptide und antikoerper vom papillomavirus, diagnostische verfahren und dieselben verwendende impfungen.
ATE41943T1 (de) Verfahren zur herstellung von polyetheramidzusammensetzungen.
Huang et al. Novel antiviral agent tetraglycylated nordihydroguaiaretic acid hydrochloride as a host-dependent viral inhibitor
FI800779A (fi) Peptider med ubikitin liknande aktivitet
DK482185A (da) Peptider, deres fremstilling og anvendelse som laegemidler
AU6920387A (en) Molecular probes, process for preparation thereof, and applications including their use for determining the sex of embryos
PT67969A (fr) Procede de preparation de derives d'amino alcools.
BR0016115A (pt) Derivados peptìdicos de acriloìla, processo para sua preparação e seu uso como agentes inibidores de tumor
DK640188D0 (da) Peptid til rensning af faktor viii, fremstilling deraf samt praeparering af faktor viii
IT1094899B (it) 4-fenil-8-amino-tetraidroisochinoline,preparati farmaceutici contenenti tali sostanze,processo per la preparazione di questi preparati e loro impiego come antide pressivi
IT8720707A0 (it) Impiego del 2,4-monofurfuriliden-sorbitolo ad uso cosmetico.
FR2670355B3 (fr) Pointe de soc de charrue en carbure.
SU629261A1 (ru) Устройство дл зажима чулочной формы
ATE150763T1 (de) Oligo-2'-desoxynukleotide und ihre verwendung als arzneimittel mit antiviraler wirksamkeit

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 386563

Country of ref document: ES